Related Experiment Video
Updated: Apr 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Recent development of anticoagulation in stroke prevention for atrial fibrillation]
Abstract:
Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation (NVAF). Warfarin has been the most common oral anticoagulant for several decades, but use of warfarin has many limitations. Recently, several novel anticoagulants that can overcome the limitations of warfarin have been developed, and some of them are already used in clinical practice in Japan. In this review, we overview the pharmacological mechanisms and the results of the phase III trial of the novel anticoagulants for preventing stroke in patients with NVAF based on the comparison to warfarin.
Insights
Novel anticoagulants offer improved stroke prevention for patients with non-valvular atrial fibrillation (NVAF), overcoming warfarin
Area of Science:
- Pharmacology
- Cardiology
- Clinical Trials
Context:
- Non-valvular atrial fibrillation (NVAF) poses a significant stroke risk.
- Warfarin has been the standard oral anticoagulant but has limitations.
- Novel oral anticoagulants (NOACs) are emerging as alternatives.
Purpose:
- To review the pharmacological mechanisms of novel anticoagulants.
- To compare the efficacy and safety of NOACs versus warfarin in NVAF stroke prevention.
- To discuss results from Phase III trials of NOACs.
Summary:
- Novel anticoagulants demonstrate efficacy in preventing stroke in NVAF patients.
- These agents offer advantages over traditional warfarin therapy.
- Phase III trial data support the use of NOACs in clinical practice.
Impact:
- Provides clinicians with an overview of NOACs for NVAF stroke prevention.
- Facilitates informed treatment decisions by comparing NOACs to warfarin.
- Highlights advancements in anticoagulant therapy for cardiovascular health.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

